We demonstrated that FXR suppresses cervical cancer by upregulating SHP, MDM2, and p53 via direct binding to SHP through the LRH-1 binding site, SHP-MDM2 complex formation, and p53 ubiquitination blockage. Here, MDM2 is linked to cervical carcinoma.